| Item Type | Name |
|
Concept
|
Sodium-Glucose Transporter 2
|
|
Academic Article
|
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
|
|
Academic Article
|
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
|
|
Academic Article
|
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
|
|
Academic Article
|
Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy.
|
|
Academic Article
|
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
|
|
Academic Article
|
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
|
|
Academic Article
|
SGLT2 Inhibitors and Mechanisms of Hypertension.
|
|
Academic Article
|
Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis.
|
|
Academic Article
|
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
|
|
Academic Article
|
Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors.
|
|
Academic Article
|
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
|
|
Academic Article
|
Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
|
|
Academic Article
|
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
|
|
Academic Article
|
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
|
|
Academic Article
|
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
|
|
Academic Article
|
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
|
|
Academic Article
|
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
|
|
Academic Article
|
U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy.
|
|
Academic Article
|
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
|
|
Academic Article
|
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
|
|
Academic Article
|
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
|
|
Academic Article
|
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
|
|
Academic Article
|
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
|
|
Academic Article
|
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
|
|
Academic Article
|
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
|
|
Academic Article
|
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
|
|
Academic Article
|
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.
|
|
Academic Article
|
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
|
|
Academic Article
|
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
|
|
Academic Article
|
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
|
|
Academic Article
|
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
|
|
Academic Article
|
Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care.
|
|
Academic Article
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
|
|
Academic Article
|
Glucose-lowering treatment patterns in patients with diabetic kidney disease.
|
|
Academic Article
|
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
|
|
Academic Article
|
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
|
|
Academic Article
|
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
|
|
Academic Article
|
The changing trajectory of diabetic kidney disease.
|
|
Academic Article
|
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
|
|
Academic Article
|
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
|
|
Academic Article
|
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
|
|
Academic Article
|
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
|
|
Academic Article
|
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
|
|
Academic Article
|
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
|
|
Academic Article
|
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
|